136 related articles for article (PubMed ID: 9196150)
1. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.
Hillner BE; Kirkwood JM; Atkins MB; Johnson ER; Smith TJ
J Clin Oncol; 1997 Jun; 15(6):2351-8. PubMed ID: 9196150
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
Hillner BE
Eur J Cancer; 1998 Jul; 34 Suppl 3():S18-21. PubMed ID: 9849404
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
Crott R; Ali F; Burdette-Radoux S
Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
[TBL] [Abstract][Full Text] [Related]
4. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
González-Larriba JL; Serrano S; Alvarez-Mon M; Camacho F; Casado MA; Díaz-Pérez JL; Díaz-Rubio E; Fosbrook L; Guillem V; López-López JJ; Moreno-Nogueira JA; Toribio J
Eur J Cancer; 2000 Dec; 36(18):2344-52. PubMed ID: 11094308
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review.
Crott R
Pharmacoeconomics; 2004; 22(9):569-80. PubMed ID: 15209526
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.
Kilbridge KL; Cole BF; Kirkwood JM; Haluska FG; Atkins MA; Ruckdeschel JC; Sock DE; Nease RF; Weeks JC
J Clin Oncol; 2002 Mar; 20(5):1311-8. PubMed ID: 11870174
[TBL] [Abstract][Full Text] [Related]
8. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
Messori A; Becagli P; Trippoli S; Tendi E
Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
[TBL] [Abstract][Full Text] [Related]
9. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma.
Wilson LS; Reyes CM; Lu C; Lu M; Yen C
Melanoma Res; 2002 Dec; 12(6):607-17. PubMed ID: 12459651
[TBL] [Abstract][Full Text] [Related]
10. Patient preferences for adjuvant interferon alfa-2b treatment.
Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
[TBL] [Abstract][Full Text] [Related]
12. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
14. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
Kirkwood JM; Resnick GD; Cole BF
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH
J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223
[TBL] [Abstract][Full Text] [Related]
17. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients.
Lee JH; Glick HA; Hayman JA; Solin LJ
J Clin Oncol; 2002 Jun; 20(11):2713-25. PubMed ID: 12039934
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
Aggarwal R; Ghoshal UC; Naik SR
Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
Liberato NL; Quaglini S; Barosi G
J Clin Oncol; 1997 Jul; 15(7):2673-82. PubMed ID: 9215840
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
